Skip to main content
AmigoFish

Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi

From The BioCentury Show · · 37 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman, President, and CEO Chris Anzalone joins BioCentury’s Stephen Hansen to discuss where siRNA has the edge over ASOs, what the Phase III miss for Novartis’ pelacarsen means for olpasiran, the Lp(a) therapy Arrowhead partnered with Amgen, and the growth outlook for plozasiran in severe hypertriglyceridemia. Anzalone also describes Arrowhead’s obesity programs targeting INHBE and ALK7, and a dimer molecule that silences two genes at once.

View full story: https://www.biocentury.com/article/661194

#RNAi #siRNA #DrugDelivery #DrugDevelopment #Biotech

0:00 Introduction 1:09 Arrowhead's siRNA Platform 9:05 Solving for Extra-Hepatic Delivery 23:43 Redemplo's Future Growth 27:00 Obesity and Bispecific siRNA

Back to The BioCentury Show · Report a problem